Prostaglandin E2 inhibits vasotocin-induced osmotic water permeability in the frog urinary bladder by EP1-receptor-mediated activation of NO/cGMP pathway

Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R528-37. doi: 10.1152/ajpregu.00811.2006. Epub 2007 Mar 15.

Abstract

PGE(2) is a well-known inhibitor of the antidiuretic hormone-induced increase of osmotic water permeability (OWP) in different osmoregulatory epithelia; however, the mechanisms underlying this effect of PGE(2) are not completely understood. Here, we report that, in the frog Rana temporaria urinary bladder, EP(1)-receptor-mediated inhibition of arginine-vasotocin (AVT)-induced OWP by PGE(2) is attributed to increased generation of nitric oxide (NO) in epithelial cells. It was shown that the inhibitory effect of 17-phenyl-trinor-PGE(2) (17-ph-PGE(2)), an EP(1) agonist, on AVT-induced OWP was significantly reduced in the presence of 7-nitroindazole (7-NI), a neuronal NO synthase (nNOS) inhibitor. NO synthase (NOS) activity in both lysed and intact epithelial cells measured as a rate of conversion of l-[(3)H]arginine to l-[(3)H]citrulline was Ca(2+) dependent and inhibited by 7-NI. PGE(2) and 17-ph-PGE(2), but not M&B-28767 (EP(3) agonist) or butaprost (EP(2) agonist), stimulated NOS activity in epithelial cells. The above effect of PGE(2) was abolished in the presence of SC-19220, an EP(1) antagonist. 7-NI reduced the stimulatory effect of 17-ph-PGE(2) on NOS activity. 17-ph-PGE(2) increased intracellular Ca(2+) concentration and cGMP in epithelial cells. Western blot analysis revealed an nNOS expression in epithelial cells. These results show that the inhibitory effect of PGE(2) on AVT-induced OWP in the frog urinary bladder is based at least partly on EP(1)-receptor-mediated activation of the NO/cGMP pathway, suggesting a novel cross talk between AVT, PGE(2), and nNOS that may be important in the regulation of water transport.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blotting, Western
  • Brain Chemistry / drug effects
  • Calcium / metabolism
  • Cyclic AMP / physiology*
  • Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide / pharmacology
  • Dinoprostone / analogs & derivatives
  • Dinoprostone / pharmacology*
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism
  • In Vitro Techniques
  • Indazoles / pharmacology
  • Male
  • Nitric Oxide / physiology*
  • Nitric Oxide Synthase Type I / antagonists & inhibitors
  • Nitric Oxide Synthase Type I / metabolism
  • Oxytocics / pharmacology*
  • Permeability / drug effects
  • Rana temporaria
  • Receptors, Prostaglandin E / physiology*
  • Receptors, Prostaglandin E, EP1 Subtype
  • Signal Transduction / drug effects*
  • Urinary Bladder / drug effects*
  • Urinary Bladder / metabolism*
  • Vasotocin / antagonists & inhibitors*
  • Vasotocin / pharmacology*
  • Water-Electrolyte Balance / drug effects*

Substances

  • 17-phenyltrinorprostaglandin E2
  • Enzyme Inhibitors
  • Indazoles
  • Oxytocics
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP1 Subtype
  • Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide
  • Nitric Oxide
  • Cyclic AMP
  • Nitric Oxide Synthase Type I
  • Dinoprostone
  • Calcium
  • 7-nitroindazole
  • Vasotocin